Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS)
Overview
Background of the study: CRPS type-1 is a pain syndrome that usually develops after an initiating noxious event (e.g. fracture) in an extremity. Although treatment options life dimethyl-sulphoxide (DMSO), N-acetylcysteine (NAC) and intensive physical therapy exist, the treatment effect is often unsatisfactory, even leading to amputation of the extremity. Surgical treatment of chronic pain disorders by dividing the sympathetic chain is an established treatment. Its more invasive nature has prevented widespread application. After introduction of minimal invasive techniques in recent years, the UMCG has now devised a truly minimal invasive, yet safe and effective thoracoscopic technique, that requires only a single 1 cm long incision in the anterior axillary line. This technique is developed as treatment for primary focal axillary and palmar hyperhidrosis, and is performed in over 50 patients producing very satisfying results. This fact has led to the hypothesis that this same surgical technique can offer this group of chronic pain patients a safe, effective treatment modality. Objective of the study: The effect of the intervention on pain an regain of function in de affected extremity. This will be quantified in multiple questionnaires at baseline and three follow-up points, and by clinical evaluation of the hand function at baseline and two follow-up points. Study design: Single center prospective feasibility study
Full Title of Study: “Single-port Thoracoscopic Sympathicotomy for Treatment of Complex Regional Pain Syndrome Type I, a Feasibility Study.”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: December 2016
Interventions
- Procedure: unilateral single-port VATS sympathicotomy
Arms, Groups and Cohorts
- Experimental: Sympathicotomy
- unilateral single-port VATS sympathicotomy
Clinical Trial Outcome Measures
Primary Measures
- Change in perceived pain measured in Visual Analogue Scale
- Time Frame: Baseline, 1, 3 and 6 months postoperative
Secondary Measures
- Change in function in extremity
- Time Frame: Baseline, 1 and 6 months after intervention
- Strength in fingers, maximal flexion/extension in all digits, volumetric measurement, timing simple daily tasks.
Participating in This Clinical Trial
Inclusion Criteria
Age 18 – 65 years.
- ASA 1 en 2. – CRPS-1 defined according to IASP-Bruehl criteria at the wrist or lower arm level. 1. Continuing pain which is disproportionate to any inciting event 2. Must report at least one symptom in each of the four following categories – Sensory: reports of hyperesthesia – Vasomotor: reports of temperature asymmetry, skin color change or asymmetry. – Sudomotor/edema: reports of edema, sweating changes, sweating asymmetry – Motor/trophic: reports of decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic changes (hair, nail, skin) 3. Must display at least one sign in two or more of the following categories: – Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch) – Vasomotor: evidence of temperature asymmetry, color changes, asymmetry – Sudomotor/edema: evidence of edema, sweating changes, sweating asymmetry – Motor/trophic: evidence of decreased range of motion, motor dysfunction (weakness, tremor, dystonia), trophic changes (hair, nail, skin) Exclusion Criteria:
Known COPD > Gold class 1.
- History of smoking > 20 pack years, due to higher risk of complications following unilateral lung- deflation and re-insufflation. – Documented substance addiction. – Previous intra-thoracic pleural drainage on affected side. – Previous thoracic surgery on affected side (including sternotomy). – Gross pulmonary or pleural abnormalities on chest X-ray. – Pregnancy, determined by preoperative pregnancy test. – Unsuitable anatomy (e.g. due to severe physical malformations).
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- University of Groningen
- Provider of Information About this Clinical Study
- Principal Investigator: Michiel Kuijpers, Principal Investigator – University of Groningen
- Overall Official(s)
- Massimo A Mariani, MD, PhD, Study Chair, University Medical Center Groningen
- Michiel Kuijpers, MD, Principal Investigator, University Medical Center Groningen
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.